Abdolkarim Moazeni-Roodi, Saeid Ghavami and Mohammad Hashemi* Pages 1 - 7 ( 7 )
Growing evidence propose an association between miRNA polymorphisms and cancer susceptibility. This study aimed to examine the impact of miR-605 rs2043556 polymorphism on cancer risk through a meta-analysis based on 3198 cancer cases and 4943 controls. Eligible studies were retrieved by searching Web of Science, PubMed, Scopus, and Google Scholar databases up to August 27, 2018. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effect model to estimate the strength of association between rs2043556 variant of miR- 605 and cancer risk. Overall, no significant association was found between miR-605 rs2043556 polymorphism and cancer risk in heterozygous codominant (OR=0.93, 95%CI=0.76-1.13, p=0.44, AG vs AA), homozygous codominant (OR=1.01, 95%CI=0.78-1.30, p=0.94, GG vs AA), dominant (OR=0.95, 95%CI=0.79-1.13, p=0.55, AG+GG vs AA), recessive (OR=1.07, 95%CI=0.84-1.38, p=0.57, GG vs AG+AA), overdominant (OR=0.93, 95%CI=0.76-1.12, p=0.43, AG vs GG+AA), and allele (OR=0.98, 95%CI=0.87-1.10, p=0.73, G vs A) genetic models tested. Stratified analysis by cancer type revealed that the rs2043556 variant was not associated with digestive tract cancer, breast cancer, gastric cancer as well as lung cancer. Taken together, the findings of this meta-analysis did not support an association between miR-605 rs2043556 polymorphism and cancer susceptibility.
miR-605, rs2043556, Polymorphism, Cancer, Meta-analysis.
Department of Clinical Biochemistry, Iranshahr University of Medical Sciences, Iranshahr, Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan